BMY reports interim results from Phase 1 trial of anti-PD-1 immunotherapy
The fully-human antibody targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1. In the dose-ranging study 003, the anti-PD-1 immunotherapy (BMS-936558), showed clinical activity
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.